珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
2024年03月01日 11:41:05来源:作者:
【摘要】 文传商讯,中国领先的新闻稿来源,由国际文传(中国)电讯社携手美国商业资讯对外提供。帮助美国商业资讯将其客户的新闻稿呈现给大中华区的目标受众,每日提供由国际文传专业记者团队报导的有关这些行业的中文新闻

ZUG, Switzerland--(BUSINESS WIRE)--Galderma:

Delivered against full year guidance for another consecutive year with strong financial performance

  • Galderma achieved net sales of 4.082 B USD, up 8.5% year-on-year on a constant currency basis1 in FY 2023, at the higher end of its 6-9% net sales growth 2023 FY guidance, and surpassed 4 B USD in net sales for the first time
    • Positive momentum across all product categories outperforming fast growing market segments, with year-on-year net sales growth on a constant currency basis of 6.5% in Injectable Aesthetics, 12.1% in Dermatological Skincare, and 8.7% in Therapeutic Dermatology
  • Core EBITDA for 2023 was 942 M USD, representing a 23.1% Core EBITDA margin, with 21.4% year-on-year growth on a constant currency basis. Core EBITDA margin expansion was significant, up 281 basis points versus prior year on a constant currency basis in line with its 2023 FY guidance range

Continued commercial execution and pipeline advancements

  • In Injectable Aesthetics, Galderma continued to outpace the market with global share gains in neuromodulators, fillers and biostimulators. The Company also announced positive results from two phase IIIb trials investigating RelabotulinumtoxinA (QM-1114), for the treatment of glabellar lines (“frown lines”) and lateral canthal lines (“crow’s feet”)
  • Dermatological Skincare flagship brands, Cetaphil and Alastin, drove substantial growth ahead of the market, with continued geographic and portfolio expansion including the launch of Cetaphil Healthy Renew, Alastin ReSURFACE Skin Polish and the C-RADICAL Defense Antioxidant Serum
  • In Therapeutic Dermatology, Galderma made progress to expand its leading portfolio and planned entry into the fast-growing biologics sub-segment. The Company showcased positive data from four phase III trials investigating the treatment of atopic dermatitis and prurigo nodularis with nemolizumab, meeting all primary and secondary endpoints across trials. On February 14, 2024, Galderma announced regulatory filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in the U.S. and EU.

2024 guidance

  • In 2024, Galderma expects to deliver 7-10% net sales growth on a constant currency basis and a Core EBITDA margin in line with 2023 at constant currency, despite significantly increased investments in nemolizumab

 

“This has been a landmark year for Galderma, underscoring the strong momentum and sustained growth we have seen over the past four years. We expect this momentum to continue in 2024 and beyond, leveraging our pure-play dermatology focus, the strong positions of our leading brands such as Cetaphil, Dysport, Sculptra and Restylane, our global scale with omnichannel execution excellence and our market leading education and services. With our robust and fully established integrated dermatology platform and our leading science and innovation, Galderma is set to continue on its strong growth trajectory.”

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER

 

 

责任编辑: admin

看新闻,关注新闻

天猫网友:Haggard. 憔悴
评论:泰坦尼克号选在2012上映是要告诉我们,作为屌丝,就算你搞到了船票,也是死路一条。

网易网友:言简而悲伤∝
评论:你都好意思骗我了,我哪好意思不信。

猫扑网友:摆摊卖青春
评论:法国有个圣女,叫贞德。中国有好多剩女,是真的。

本网网友:ゆ.舌尖腥咸
评论:人生就是这样:不是你混日子;就是日子把自己混了

淘宝网友:迩卜Sんī涐旳谁
评论:有一个胖子,从二十楼顶往下跳。结果变成了… 死胖子!!

百度网友:红酒 高跟鞋 性感seduce
评论:做女孩一定要经的起谎言,爱的起敷衍,忍的了欺骗,忘得了诺言,放的下一切,最后用笑来伪装你的泪眼!

凤凰网友:惜一丝清冷
评论:黄瓜是用来拍的,人生是用来嗨的

其它网友:我依舊依賴你
评论:都说炫舞里面的人物身材好,我告诉你,你要是天天那么蹦跶你也瘦。

腾讯网友:失控-  Tender
评论:他看事总乐观,看人总悲观!

搜狐网友:他就是我的天
评论:钱多钱少,够吃就好。人丑人美,顺眼就好。人老人少,健康就好。家穷家富,和气就好。

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!